Abstract: Improvementoft he accuracy of dosimetry in radionuclide therapy has the potentialt oi ncreasep atient safety and therapeutic outcomes. Althoughp ositron emission tomography (PET) is ideally suited for acquisition of dosimetric data because PET is inherently quantitative and offersh igh sensitivity and spatialr esolution, it is not directly applicable for this purpose because common therapeutic radionuclides lack the necessary positrone mission. This work reports on the synthesis of dual-nuclide labeled radiopharmaceuticalsw ith therapeutic and PET functionality,w hich are based on common and widely available metal radionuclides. Dual-chelator conjugates, featuring interlinked cyclen-and triazacyclononane-based polyphosphinates DOTPI and TRAP,a llow for strictly regioselective complexation of therapeutic (e.g., 177 Lu,
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Radionuclide therapy [1] (also termed molecular radiotherapy) is the internal application of radionuclides or radiolabeled compounds for therapeutic purposes,a bove all, for treatment of cancer.I nt his context, the term "dosimetry" referst ot he assessment of absorbed radiatione nergy per tissue volume, derived from spatially resolved radioactivity distribution data over time. Hence, the averagely delivered tissued oses of ar adiotherapeutic are governed by many factors, such as the decay characteristics of the radionuclide used, the radiopharmaceutical's metabolic stability, excretion kinetics and route, its target affinity and specificity,a nd its specific uptakea nd retention in targeted as well as in non-targeted organsa nd tissues. However,i ndividual doses may vary [2] because uptakeo f ar adiopharmaceuticali nt umors and in organs andt issues at risk is also dependento nm ethodological and patient-specific factors, such as variations of the administered mass dose of the radiopharmaceutical, [3] [4] [5] [6] [7] cumulative tumor mass, [8] tumor perfusion, [9] expression density of the target (e.g.,o fasurface receptor) on tumor cells, [10, 11] individuala nd gender-dependent metabolic rates, body weighto ra ltered excretion kinetics( e.g., renal impairment).Apersonalizedd osimetry is thus an ecessary prerequisite to assess such interindividual variations in clinical trials, in order to optimize treatment protocols, to maximize tumord oses, to improvet he individual therapeutic outcome, and to increase patient safety. [2, 12] For targeted radionuclide therapy,s pecific receptor ligands or enzymei nhibitors (e.g.,o ligopeptides or peptoids) are usually equipped with suitable chelators [13] (mostly based on the structuralm otif DOTA) [14] and labeled with radiometali ons, such as the b [15] Dosimetry usually relies on planars cintigraphy or single-photon emissionc omputed tomography (SPECT), [16, 17] exploiting additional g-emissions of these nuclides, or by "spiking" with am atched g-emitter (e.g., partially replacing 90 Y III ,w hichh as no photone mission, with 111 In III ). [18] In this context,i th as been pointedo ut earlier that positrone mission tomography( PET) is particularly attractive for acquiring dosimetric data, because PET is very sensitivea nd capable of quickly delivering quantitative spatial distribution data with high resolution, and is thus, in principle, superior to SPECT and scintigraphy. [19] However,v irtually all therapeutic radiometals are lacking the necessary b + -emissions. Hence, spiking with a b + -emitting isotope of the same elementh as been recommended, for example, ap artial replacement of 90 Yw ith 86 Y, [20] which enabled improved dosimetry compared to 111 In-SPECT. [21, 22] Apart from the fact that this approach is not applicable to elements devoid of b + -emittingi sotopes, such as Bi, it suffers from insufficient availability of all relevant surrogate PET nuclides. Furthermore, many of them exhibit unfavorable decay properties, such as additional highenergy gamma lines, which challengeP ET quantitation by false coincidences due to scatterp hotons and cause high radiation doses to operating and nursing personnel.
Alternatively, the therapeutic metal ion can be exchanged withachemically different b + -nuclide, such as 68 Ga III . [23] [24] [25] Indeed, pre-therapeutic PET scans obtained with 68 Ga-DOTA-peptides are frequently employed for therapy decisions, [3, 4, 26] whereas their value for dosimetry is limited due to mismatching half-lives( 68 min for 68 Ga vs. severald ays for 90 Yo r 177 Lu). Furthermore, this approach inherently lacks precisionb ecause 68 Ga III -a nd other radiometalated DOTA-conjugates frequently exhibit different targetto-organ ratios [27, 28] due to deviations in pharmacodynamics, which in turn result from different polarities owing to mismatched coordination modes (Ga III -DOTA: hexadentate, zwitterionic;L n III -, Sc III -, Y III -, Bi III -DOTA: nona-or octadentate, uncharged). [13] To overcome these limitations, we herein propose radiopharmaceuticals bearing both at herapeutic and aP ET-radiometal at defined locations.W ep rimarily focusedo nt he emerging therapeutic a-emitter 213 Bi, [15] because in view of its short half-life (T1 = 2 = 46 min), accuracy of dosimetry particularly benefits from the high temporal resolution achievable by dynamic PET. 68 Ga III (T1 = 2 = 68 min) ideallyc omplements 213 Bi in terms of half-life and accessibility as both are obtainedf rom commerciallya vailable radionuclide generators( small chromatographic benchtop devices acting as regenerative nuclide sources). [15, [23] [24] [25] To achieve regiospecific complexation of Ga III and Bi III ,wedecided to exploit the complementary metal ion selectivity of the homologousp hosphinate chelators DOTPI [29] (large trivalent cations)a nd TRAP [30] (small trivalent cations, particularly Ga III ), [31] [32] [33] which were linked through their N-pendant arms (Scheme 1). First, DOTPI was equipped with four terminal azide groups.E mploying CuAACo rS PAAC, DOTPI(azide) 4 was further decorated with three copieso fP A-Ahx-KuE or DBCO-Ahx-KuE, wherein KuE (glutamic acid-urea-lysine) is an inhibitor motif for prostate-specific membrane antigen (PSMA, EC 3.4.17.21, synonyms:g lutamate carboxypeptidase II, NAALADase; [34] am embrane-bound zinc hydrolase that is overexpressed by malignant human prostate cancers). Subsequent conjugation of TRAP was done by CuAAC couplingo fT RAP-monopropargylamide [35] followed by competitive Cu-demetalation, [36, 37] leading to the PSMA inhibitor trimers DOTPI(PA-Ahx-KuE) 3 (TRAP) (1) and DOTPI(DBCO-Ahx-KuE) 3 (TRAP) (2)( Scheme 1; isolated yields were 19 and 10 %, respectively,b ased on DOTPI(azide) 4 ).
To demonstrate the feasibility of the concept not only for Bi III but for radiolanthanides in general,p recursors for radiometal complexation wereprepared from 1 and 2 by complexation of DOTPI with M III (M = Lu, Bi)o ro fT RAP with Ga III accordingt o Scheme 2. In either case, both chelatorc ages were initially saturatedu sing an excess of the respective metal ion. Subsequently,s electiver emoval of M III from TRAP and Ga III from DOTPI, respectively,was achieved by exploiting the substantially different coordination behavior of the complexes. Because neither the [M III (TRAP)] [38, 39] nor the [Ga III (DOTPI)] [29] system is particularly stable or kinetically inert, removal of metal ions from these chelates is feasible by means of transchelation with (aq.) Na 3 DTPAo rN a 2 68 Ga applying as tandard automated protocol [40] and administered to SCID mice bearing LNCaP (human prostatec arcinoma) xenografts ( Figure 2 Table 1 ). The DBCO-moieties of compound 2 effect as lightly lower degree of hydrophilicity compared to 1 (À3.8 AE 0.1 vs. À4.4 AE 0.1, respectively). Because of the multimer effect, PSMA affinities (expressed as IC 50 ,d etermined in displacement assays on LNCaP cells) of compounds 1 and 2 are high (2.5 AE 0.2 and 2.8 AE 0.3 nm, respectively) and exceed those of clinically applied PSMA ligands. [41, 42] In conclusion, we have shown that interlinked chelators with orthogonal kinetic inertness profilesp rovide facile access to pairs of 68 Ga-PET tracers and radiometal therapeutics with identicalc hemical structure. Co-injectiona llows for monitoring the in vivo III .L ikewise, precursors for labeling with 68 Ga are produced by selective complexation of the inactive M III isotopes. The generic "R" refers to any possible substituent, not implicating similarity of any residues involved.
Chem. Eur.J. 2018, 24,547 -550 www.chemeurj.org 2018 The Authors. Published by Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim distribution of the radiotherapeutics by PET and thus enables therapeutic dosimetry with improvedprecision and accelerated workflows. Although the synthetic approacha llows the use of any radiolanthanide, the prerequisite of matching half-lives suggestsp rimary use with 213 Bi. Notwithstandingt his, the possibility of performing fast and accurate PET-based dosimetry for 213 Bi-labeled therapeuticsmight further promote 213 Bi-based alpha-therapy,representing al ast option for cancer patients refractoryt oe stablished externalo ri nternal radiation treatments.
